国际视角下2019年ATS/IDSA社区获得性肺炎指南的深度解读:全球专家组的批判性评价
该文由来自五大洲10个国家的14位国际肺炎专家,对2019年ATS/IDSA社区获得性肺炎(CAP)指南在美国以外地区的适用性进行主观评价。专家们欢迎废除“医疗保健相关肺炎”概念、限制门诊大环内酯类经验性用药指征、强调微生物学诊断及讨论糖皮质激素使用;主要批评包括门诊大环内酯类单药治疗25%耐药阈值的任意性,以及高分枝杆菌流行区专家反对氟喹诺酮类推荐。
要点
- 国际专家支持废除医疗保健相关肺炎概念,并限制门诊大环内酯类经验性使用。
- 门诊大环内酯类单药治疗的25%耐药阈值被批评为缺乏充分依据。
- 高分枝杆菌流行地区专家尤其反对将氟喹诺酮类作为替代推荐。
核心结论
- 2019年ATS/IDSA CAP指南的部分推荐在国际范围内获得认可,但耐药阈值和氟喹诺酮类推荐在部分地区存在争议。
研究设计与样本
- 由来自五大洲10个国家的14位国际CAP专家组成专家组,未参与2019年指南制定,主观提名五项最有用的改变、最受批评的推荐及无法应用于本地区的推荐,无正式共识流程。
主要发现
- 多数专家欢迎废除医疗保健相关肺炎概念、限制门诊大环内酯类经验性用药指征、加强微生物学诊断及讨论糖皮质激素使用。
- 主要批评包括门诊大环内酯类单药治疗25%耐药阈值的任意性。
- 高分枝杆菌流行地区专家尤其反对氟喹诺酮类推荐,即使作为替代方案。
关键数值与推荐
- 门诊大环内酯类单药治疗的耐药阈值为25%。
临床怎么用
- 在美国以外应用ATS/IDSA CAP指南时,应结合当地微生物学病因和耐药情况,审慎评估大环内酯类和氟喹诺酮类的使用。
局限性
- 无正式共识流程,文章反映不同专家意见,非系统评价。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 2019, the American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) issued a substantial revision of the 2007 guideline on community-acquired pneumonia (CAP). Despite the fact that generalization of infectious disease guidelines is limited because of substantial geographic differences in microbiologic etiology and antimicrobial resistance, the ATS/IDSA guideline is frequently applied outside the United States. Therefore, this project aimed to give a perspective on the ATS/IDSA CAP recommendations related to the management of CAP outside the United States. For this, an expert panel composed of 14 international key opinion leaders in the field of CAP from 10 countries across five continents, who were not involved in producing the 2019 guideline, was asked to subjectively name the five most useful changes, the recommendation viewed most critically, and the recommendation that cannot be applied to their respective region. There was no formal consensus process, and the article reflects different opinions. Recommendations welcomed by most of the international pneumonia experts included the abandonment of the concept of "health-care-associated pneumonia," the more restrictive indication for empiric macrolide treatment in outpatients, the increased emphasis on microbiologic diagnostics, and addressing the use of corticosteroids. Main criticisms included the somewhat arbitrary choice of a 25% resistance threshold for outpatient macrolide monotherapy. Experts from areas with elevated mycobacterial prevalence particularly opposed the recommendation of fluoroquinolones, even as an alternative.
引用
- Pletz MW, Blasi F, Chalmers JD, et al. International Perspective on the New 2019 American Thoracic Society/Infectious Diseases Society of America Community-Acquired Pneumonia Guideline: A Critical Appraisal by a Global Expert Panel. Chest. 2020. PMID: 32858009. doi:10.1016/j.chest.2020.07.089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。